Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Anand V. Kulkarni,[a,*] Harshvardhan Tevethia,[b] Karan Kumar,[c] Madhumita Premkumar,[d] Mark D. Muttaiah,[e] Atsushi Hiraoka,[f] Takeshi Hatanaka,[g] Toshifumi Tada,[h] Takashi Kumada,[i] Satoru Kakizaki,[j] Arndt Vogel,[k] Richard S. Finn,[l] Padaki Nagaraja Rao,[a] Anjana Pillai,[m] Duvvur Nageshwar Reddy,[a] and Amit G. Singal[n]

[a]Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India
[b]Department of Hepatology, ILBS, New Delhi, India
[c]Department of Hepatology, Mahatma Gandhi Medical College, Jaipur, India
[d]Department of Hepatology, PGIMER, Chandigarh, India
[e]Yong Loo Lin School of Medicine, National University of Singapore, Singapore
[f]Gastroenterology Centre, Ehime Prefectural Central Hospital, Matsuyama, Japan
[g]Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan
[h]Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Hyogo, Japan
[i]Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan
[j]Department of Clinical Research, National Hospital Organization Takasaki General Medical Centre, Takasaki, Japan
[k]Medizinische Hochschule Hannover, Hannover 30625, Germany
[l]Division of Hematology/Oncology, Department of Medicine, Geffen School of Medicine at UCLA, Santa Monica, CA, USA
[m]Division of Gastroenterology, Hepatology and Nutrition, Chicago, IL, USA
[n]Department of Medicine, UT Southwestern Medical Centre, Dallas, TX, USA

Summary

Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness and safety in other populations, including those with Child-Turcotte-Pugh (CTP) class B cirrhosis, is unclear.

Methods For this systematic review and meta-analysis, electronic databases, including PubMed, Embase, and Scopus, were searched from 1st May, 2020 till 5th October, 2022; the last date of access was January 31, 2023. Pooled progression-free survival (PFS), overall survival (OS), and radiological response rate among patients receiving atezo-bev were compared between patients with CTP-A and CTP-B cirrhosis, with tyrosine kinase inhibitors (TKIs) and among those receiving the drug as first-line and later line therapy. The protocol was registered in Prospero (CRD42022364430).

Findings Among 47 studies (n = 5400 patients), pooled PFS and OS were 6.86 (95% CI, 6.31–7.41) and 13.8 months (95% CI, 11.81–15.8), respectively. Objective response rate (ORR) and disease control rate were 26.7% (24.6–29.1) and 75.3% (73.1–77.4) using RECIST criteria, and 34% (30.3–37.8) and 73.6% (68.8–78) using mRECIST criteria, respectively. Among those receiving atezo-bev, patients with CTP-B cirrhosis had similar ORRs by RECIST (odds ratio [OR], 1.42 [0.77–2.6]; P = 0.25) and mRECIST criteria (OR, 1.33 [0.52–3.39]; P = 0.53) but shorter PFS (mean difference [MD]:3.83 months [1.81–5.84]) than those with CTP-A cirrhosis. Compared to patients receiving TKIs, those receiving atezo-bev had longer PFS (MD: 2.27 months [0.94–3.5]) and higher ORR (RECIST: OR, 1.44 [1.01–2.04] and mRECIST: OR, 1.33 [1.01–1.75]). Compared to first-line therapy, later-line therapy had lower ORR (RECIST: OR, 1.82 [1.3–2.53]; P < 0.001 and mRECIST: OR, 2.02 [1.34–3.05]) but comparable PFS (MD: 0.58 months [−0.18 to 1.35]) among nine studies. The incidence of grade ≥3 adverse events among patients with CTP-A and CTP-B cirrhosis was comparable (OR, 0.89 [0.45–1.74]) as it was for patients receiving atezo-bev and TKIs (OR, 0.86 [0.61–1.2]).

Interpretation Our findings suggest that atezo-bev is safe and effective as first-line systemic therapy for patients with uHCC and CTP-A or CTP-B cirrhosis.

Funding An unsolicited grant from ROCHE Products India Pvt Ltd. was received for publication.

*Corresponding author. Department of Hepatology and Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India.
    E-mail address: anandvk90@gmail.com (A.V. Kulkarni).

Research in context

Evidence before this study

Atezolizumab-bevacizumab (atezo-bev) is the preferred therapy for patients with unresectable HCC (uHCC) and Child-Turcotte-Pugh (CTP) class A cirrhosis based on level I data showing increased efficacy versus sorafenib. There are limited data evaluating the effectiveness of atezo-bev in extended patient populations, including those with CTP class B or in the second-line setting. Therefore, we performed a meta-analysis of patients with uHCC treated with atezo-bev. We used the following search terms: MeSH terms of "carcinoma, hepatocellular," "drug therapy, combination," and "antibodies, monoclonal" for PubMed; keywords of "monoclonal antibody" and "liver cell carcinoma" for Embase; and "atezolizumab and bevacizumab" and "hepatocellular and carcinoma" for Scopus to identify relevant articles published between 1 May, 2020 and 5 October, 2022. Only a few systematic reviews were found, including 400–500 patients treated with atezo-bev.

Added value of this study

Our systematic review identified 47 articles, including 5400 patients with uHCC treated with atezo-bev. Cumulative progression-free survival (PFS) and overall survival were 6.86 months (95% confidence interval [CI], 6.3–17.41) and 13.8 months (95% CI, 11.81–15.8), respectively. Although PFS with atezo-bev was better in CTP-A than in CTP-B, objective response rate (ORR) and incidence of adverse events were comparable. Atezo-bev yielded better ORRs in the first-line setting than in the second-line setting among nine studies. Our findings suggested that patients treated with atezo-bev in clinical practice had higher ORR and lower mortality than those treated with TKIs, although this difference was mitigated when compared to lenvatinib.

Implications of all the available evidence

Available data suggest that atezo-bev is a safe and effective therapy among patients with CTP-A or B cirrhosis.

Introduction

The incidence and mortality of hepatocellular carcinoma (HCC) has significantly increased worldwide in recent years.[1,2] Over 90% of HCCs occur in patients with underlying chronic liver disease, and HCC is a major cause of morbidity and mortality in patients with cirrhosis.[3] The poor prognosis of HCC has historically been related to a combination of late-stage presentation and ineffective therapies in those beyond an early stage. HCC treatment has evolved due to improved therapies, a better understanding of tumour biology, and increasing use of multidisciplinary management.[4,5]

Systemic therapy remains the treatment of choice for patients with unresectable HCC (uHCC). The tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, provide a comparable overall survival (OS) of 10–13.5 months for patients with uHCC, although lenvatinib can achieve higher objective response rate (ORR) and progression-free survival (PFS) than sorafenib.[6–10] However, neither of these drugs is effective in achieving a complete response (CR) on radiological evaluation. In 2020, the IMBrave150 trial demonstrated significantly improved PFS and overall survival (OS) with atezolizumab-bevacizumab (atezo-bev) compared to sorafenib.[11] With median OS reaching 19.2 months, atezo-bev is now considered a preferred first-line therapy for patients with uHCC.[12] However, the IMBrave 150 trial evaluated the efficacy of atezo-bev compared to sorafenib and its effectiveness compared to TKIs, including lenvatinib, in clinical practice is important to

understand. Further, though approved as a front-line agent, the effectiveness of atezo-bev in the second-line immuno-oncological naïve setting after the failure of front-line TKIs is unknown. Like all other phase 3 studies, the IMBrave 150 trial only included patients with Child-Turcotte-Pugh (CTP) class A (CTP-A), whereas many patients in clinical practice have worse liver dysfunction at the time of HCC presentation. Understanding the safety of atezo-bev in this patient population is particularly important, given potential concerns about variceal bleeding.

Several real-world studies have examined outcomes in patients with uHCC receiving atezo-bev and provided insights into its effectiveness and safety in these extended populations. To date, only a few meta-analyses have reported the safety and effectiveness of atezo-bev, based on one to two studies.[13,14] An updated meta-analysis is merited due to the rapid increase in the use of atezo-bev in real-world settings. Therefore, our systematic review and meta-analysis aimed to evaluate: a) ORR, cumulative PFS, and OS in patients treated with atezo-bev for uHCC; b) effectiveness and safety in patients with CTP-B cirrhosis and later line of therapy; c) effectiveness and safety of atezo-bev compared to TKIs in clinical practice.

Methods

Search strategy and selection criteria

We followed the latest Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines for data extraction and reporting.[15] We

conducted a computer-assisted search of PubMed, Embase, Google Scholar, and Scopus to identify relevant articles published between 1 May, 2020 and 5 October, 2022; the last date of access was January 31, 2023. We used the following search terms: MeSH terms of "carcinoma, hepatocellular" "drug therapy, combination," and "antibodies, monoclonal" for PubMed; keywords of "monoclonal antibody" and "liver cell carcinoma" for Embase; and "atezolizumab and bevacizumab" and "hepatocellular and carcinoma" for Scopus (Appendix I). Abstracts from the annual meetings of the American Association for the Study of Liver Disease, International Liver Cancer Association, European Association for the Study of Liver (EASL), Asian Pacific Association for the Study of Liver, and European Society for Medical Oncology (ESMO) were also searched for relevant data.

Studies were included if they reported clinical outcomes (safety or effectiveness) among adult patients with uHCC who received atezo-bev therapy, regardless of the CTP class and line of treatment. When comparing first-line vs. second-line, we included studies that reported the line of therapy in detail. If this was not reported and authors could not provide those details when contacted, studies were excluded from first-vs. second-line subgroup analysis. We included randomised controlled trials (RCTs) and prospective and retrospective cohort studies (observational studies). Exclusion criteria included studies that reported the use of other immuno-oncological agents and/or reported only treatment with TKIs. Case reports, case series, mechanistic and experimental studies, editorials, guidelines, correspondences, and book chapters were excluded. We excluded review articles that did not include original data. We also excluded studies with incomplete data, and those reporting the same database or secondary analyses of the same data. Titles containing retracted/erratum were excluded. For publications or updated analyses from the same authors, the corresponding author was contacted for the best study to be included in the final analysis. If the author did not respond, the latest peer-reviewed published data was included in the final analysis.

All the citations were first imported into Endnote ver. 20.4. One investigator (AVK) reviewed citations from the search strategy to generate a list of potentially relevant articles. If the applicability of a study could not be determined by title or abstract alone, the full text was reviewed. Ethical approval and consent forms were waived as this was a meta-analysis.

Data collection
For each study, we recorded the number of patients, duration of follow-up, line of systemic therapy (first-line or later-line), age, sex, aetiology of HCC, liver disease severity including CTP class, Barcelona Clinic Liver cancer stage (BCLC), albumin-bilirubin (ALBI) grade, and Eastern Cooperative Oncology Group (ECOG) performance status. We also retrieved data on the proportion of patients with extrahepatic spread (EHS), macrovascular invasion (MVI), and alpha-feto protein (AFP) levels $\geq$400 ng/mL.

We captured the best radiological response based on both the Response Evaluation Criteria In Solid Tumours (RECIST) and modified RECIST (mRECIST) criteria.[16] This radiological response assessment depends on the radiologist and can be variable and may introduce heterogeneity. Both ORR and disease control rate (DCR) was recorded, and the numbers of patients with CR, partial response (PR), stable disease (SD), and progressive disease (PD) were also calculated. Data were extracted by two separate individuals (HVT and KK), which were cross-checked by a third investigator (AVK), and any discrepancy was corrected after discussion.

Definitions
The baseline characteristics at the time of initiation of therapy were included for analysis to assess the patient demographics. OS was defined as the time from administration of the first atezo-bev dose to death. PFS was the time from atezo-bev initiation to death or disease progression.

Our primary outcomes were cumulative PFS, OS, ORR, and adverse events (AEs) in patients with uHCC treated with atezo-bev. Subgroups of interest included CTP-A vs. CTP-B, first-line vs. second-line therapy, and viral and non-viral aetiology. A secondary outcome was the effectiveness (ORR, PFS, and OS) and safety of atezo-bev compared to TKIs. The radiological response was evaluated using the RECIST and mRECIST criteria, when possible, and the cumulative responses were compared.

Quality assessment
The New Castle Ottawa scale (NOS) and the Cochrane tool were used to assess the quality of observational (cohort) studies and RCTs.[17,18] Cohort studies were evaluated based on three criteria: selection (maximum 4 stars), comparability (maximum 2 stars), and outcome (maximum 3 stars). Selection included representatives of the exposed (1 star), selection of nonexposed cohort (1 star), determination of exposure (1 star), and demonstration that the outcome of interest was not present at the beginning of the study (1 star). The evaluation of the outcome of interest (1 star) with sufficient duration (1 star) and adequate follow-up (1 star) was part of the outcome assessment according to NOS. Based on NOS, the studies were classified as high (8–9 stars), moderate (6–7 stars), and low quality (<6 stars). RCTs were classified as having a high, low, or unclear risk of bias based on selection bias (random sequence generation, allocation concealment), selective reporting, blinding (performance and detection bias), attrition bias (method to address incomplete data), and other biases based on the

Cochrane risk of the bias assessment tool.[18] The quality of the study was assessed for each outcome by two individuals separately (HVT and KK). In case of discrepancy, a final score was assigned after a discussion with a mediator (AVK).

Statistical analysis

The baseline data were assessed using SPSS v. 29 (IBM Corp, New York, USA). Meta-analysis was performed using comprehensive meta-analysis software (CMA ver 4.0, 2022, USA). For continuous data, the median OS and PFS were entered along with the sample size, and the cumulative survival was reported as a mean with a 95% confidence interval (CI). The median was considered as the mean given an assumption of normal distribution, and the standard deviation was calculated as per the formula: $standard\ deviation = square\ root\ N\ x\ (upper\ limit - lower\ limit)/3.92$ for sample size >100 and the denominator was changed to 4.128 for sample size <60. Otherwise, the denominator was calculated in excel using = tinv (1−0.95, n-1) and used for the SD calculation. This method was used for calculating the mean difference in PFS among CTP-A and B, and ALBI grades. If the authors reported only the mean (or median), then the mean and sample size, along with the individual P-values reported by the primary studies, were input to compare different groups. This method (mean difference [MD]) was used for comparing PFS between atezo-bev and TKIs, first- and second-line therapy, and OS among different CTP classes and ALBI grades. ORR and DCR derived from each study were entered as a percentage (event rate) along with the sample size, and the cumulative ORRs and DCRs are presented with 95% CI. To assess the cumulative radiological response (CR, PR, SD, and PD), the number of events in each group was entered along with the sample size assessed and reported as cumulative rate with 95% CI.

Meta-analysis was performed using random effects models, and the prediction interval (for certainty assessment) was reported using Forest plots. Heterogeneity was assessed using measures I^2 and Q. P-values <0.1 were considered statistically significant. Given anticipated significant heterogeneity due to the inclusion of studies with different lines of therapy (i.e., first vs. second line), patient characteristics (e.g., Child-Pugh class), and clinical settings (e.g., geographic location), we performed several sub-group analyses where feasible. Finally, publication bias was quantitatively evaluated using Egger's regression intercept test and qualitatively by visual examination of the symmetry of the funnel graph.

Registration and protocol

The protocol was registered in Prospero (CRD420 22364430), and the data were abstracted according to a priori protocol.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had access to the data and accept the responsibility to submit for publication after approving the final draft.

Results

Study and patient characteristics

Three of the 181 studies sought for retrieval were excluded as they could not be retrieved.[19–21] Of the remaining 178 articles, 43 were found to be eligible and were included in the meta-analysis. Four abstracts (through manual search) were also included in the analysis. In total, 47 studies, including 5400 patients with HCC treated with atezo-bev, were included in the analysis[11,22–67] (Fig. 1:Flow chart) (Table 1 and Supplementary Table S1). The median duration of follow-up was 8.2 months.

Of the 5400 included patients, 4473 patients received atezo-bev as first-line systemic therapy, whereas 900 received atezo-bev as second-line (or later-line) therapy, while the line of therapy was unclear among 27 patients. Twelve articles compared the outcomes of first vs. later-line therapies among 604 patients and 521 patients, respectively. Of them five studies provided the details of prior therapies: 124 had received lenvatinib, 60 had received sorafenib, 29 had received regorafenib, 10 had received ramucirumab, and 13 patients had received more than one prior therapy.[22,38,54,60,62] Dosing of the drug was uniform in all studies: atezolizumab 1200 mg and bevacizumab 15 mg/kg, except in the four studies (three from Taiwan and one from Japan). Kuwano et al., Teng et al., and Wang et al., reported the administration of bevacizumab at a dose of 5–7.5 mg/kg, whereas Su et al. reported a fixed dose of 500 mg of bevacizumab administration for all patients.[44,56,60,65] Approximately 63% (1212/1921) of patients among 17 studies reported some form of prior locoregional therapy (LRT), and 26% (423/1639) of patients among 14 studies reported surgical intervention before systemic therapy. Two studies reported prior LRT and surgery (combined) in 78.3% (137/175) of the patients.[36,55] All these studies reported the use of systemic therapy following locoregional therapy or surgery except for the study by Cheng et al., Su et al., and Xin et al., which reported the use of atezo-bev concurrently with locoregional therapy (n = 79).[27,56,66]

Among the 42 studies that reported the age and sex distribution, the median age was 69 years, and men comprised 81.5% (4233/5194). Of 39 studies (n = 4949) that reported HCC aetiology, a viral cause was reported among 60% (2966/4949) of patients, whereas 40% (2013/4949) patients had a non-viral aetiology (of which 30 had dual aetiology).[55,64] Among the reported viral causes, hepatitis B virus (HBV) infection accounted for 56% (1638/2925), hepatitis C virus infection (HCV) for

Fig. 1: PRISMA chart.

44% (1287/2925), and HBV + HCV coinfection 0.2% (7/2925). The distribution of the CTP class among 4854 patients and 41 studies were CTP-A: 88.5% (4295/4854), CTP-B: 10.7% (516/4854), and CTP-C: 0.6% (30/4854). Himmelsbach et al. could not assess four patients, and nine noncirrhotic patients in the study by Sinner et al. were excluded from the CTP classification.[39,55]

ECOG performance status was reported in 27 studies, including 3991 patients. A majority of treated patients had good performance status (63.2% [2525/3991] ECOG 0 and 27.31% [1090/3991] ECOG 1). Only 9.4% were ECOG 2 (375/3991) and <0.5% ECOG 3 (1/3991).

BCLC staging was reported in 38 studies, including 3854 patients. Most patients were in BCLC-C stage (65.7%; 2532/3854), with 31.3% (1205/3854) of patients having BCLC-B stage, 2% (61/3854) in BCLC-A stage, and 1% (37/3854) BCLC-D stage at the time of atezo-bev initiation. Only seven patients with BCLC-0 received atezo-bev therapy in the study by Tanaka et al.[59] In the study by Sinner et al., nine patients without cirrhosis and three patients in the Vithayathil et al. study did not have complete data to report the BCLC class.[55,64]

In the 38 studies that reported MVI for 4816 patients, 29% (1396/4816) had MVI. In the 39 studies that reported EHS for 4907 patients, 44% (2144/4907) had EHS. Twenty-two studies reported that 36% (1048/2913) of patients had AFP levels ≥400 ng/mL.

Six studies compared the effectiveness of atezo-bev with TKIs (n = 1918; sorafenib-165; lenvatinib-1753).[11,24,41,47,50,56] (Supplementary Table S2) The median age in the TKI group was 70.8 years, and 79.8% (1532/1918) were men. Among four studies that reported prior LRT, 75% (n = 1276/1700) had received some form of LRT, and among two studies, 29% (424/1467) had undergone surgical intervention before receiving TKIs. The reported aetiology was viral in 59.4% (1139/1918) of patients. Of the four studies that reported viral aetiology details among 1064 patients, HBV and HCV infections accounted for 45% (479/1064) and 55% (585/1064), respectively.[11,24,41,50] Except for the study by Niizeki et al., the remaining studies reported CTP class and ECOG performance status among 1766 patients. Approximately 91% (1606/1766) were patients with CTP-A cirrhosis, and only 9% (160/1766) had CTP-B cirrhosis. The majority of patients had good performance status (71.2% [1345/1766] ECOG 0 and 23.8% [421/1766] ECOG 1–2). The study by Casadei-Gardini et al. did not report BCLC staging. Most patients were in BCLC-C stage (67.7%; 389/575), whereas 30% were in BCLC-B stage (174/575) and 2% (12/575) BCLC-A stage. Among the six studies, 26% (500/1918) patients had MVI, and 39.6% (759/1918) had EHS. Two studies reported that 34.2% (72/211) of patients had AFP levels ≥400 ng/mL.

No.	Name. Country. Year[ref.]	Total N	Age (years)	Males/ Females (n)	Etiology (n)	Child class (n)	BCLC (n)	Albi (n)	MVI (n)	EHM (n)	AFP > 400 ng/ mL (n)
1	Ando et al. Japan. 2021[21]	40	69 (47–90)	30/10	Viral-26 others-14	A-40	B-18 C-22	1/2a-23 2b-17 3-0	12	16	
2	Awiwi et al. USA. 2022[22]	55	66 (36–80)	45/10		A-30 B-25			5	18	27
3	Casadei-Gardini et al. Italy, Germany, Portugal, Japan and the Republic of Korea. 2022[23]	864	72 (65–79)	682/182	HCV-299 HBV-184 NASH-126	A-778 B-86			188	314	
4	Charonpongsuntorn et al. Thailand. 2022[24]	30		–							
5	Chen et al. Taiwan. 2022[25]	41	65 (25–84)	38/3	HBV-30 HCV-8 Others-4	A-28 B-6 C-7	–	1-7 2a-11 2b-19 3-4	30	30	18
6	Cheng et al. China. 2022[26]	13				A-8 B-5	BCLC C-13				
7	Cheon et al. Korea, 2021[27]	121	61 (36–83)	101/20	HBV-93 HCV-6 Nonviral-22	A-121	B-25 C-96	1-65 2-56	45	85	46
8	Chon et al. Korea. 2021[28]	121	63 (57–71)	100/21	HBV-83 HCV-7 Nonviral-31	A-121	B-20 C-101	1-67 2-54 3-0	50	68	
9	Chuma et al. Japan. 2021[29]	94	73 (37–87)	73/21	HBV-18 HCV-31 Others-45	A-82 B-13	A-1 B-45 C-48	1-31 2a-27 2b-33 3-3	22	32	
10	Cosgrove et al. USA. 2022m[30]	166	69 (32–88)	126/40				2-92 3-15			49
11	D-Alessio et al. Asia/Europe/USA. 2022[31]	202	69 (23–90)	173/29	HBV-35 HCV-72 Others-92	A-154 B-48	A-3 B-55 C-144	1-71 2-118 3-13	80	77	65
12	De Castro et al. Germany/Austria. 2022[32]	147	68.7 (30–96)	125/22	Alcohol-39 HBV-12 HCV-38 NASH-34 Others-24	A-106 B-35 C-6	A-1 B-23 C-116 D-7	1-51 2-83 3-13	48	65	52
13	Eso et al. Japan. 2021[33]	40	70.5 (53–82)	35/5	HBV-6 HCV-13 Others-21	A-38 B-2	B-21 C-19	1-16 2a-12 2b-12			
14	Finn et al., Global. 2021[11]	336	64 (56–71)	277/59	HBV-164 HCV-72 Others-100	A-335 B-1	A:8 B:52 C:276		129	212	126
15	Fulgenzi et al. Europe, Asia and USA. 2022[34]	296		245/51	HBV-120 HCV-75 Others-101	A-296	B-92 C-204	1-161 2-133 3-2	104	169	102
16	Ha et al. Korea. 2022[35]	125	63	103/22	HBV-87	A-113 B-12					
17	Ha and Kim et al. Korea. 2022[36]	194	62.1	166/28	HBV-128 Others-66	A-165 B-27 C-2		1-104 2-86 3-4	28	119	
18	Hayakawa et al. Japan. 2021[37]	52	73 (24–89)	42/10	HBV-10 HCV-20	A-48 B-4	B-29 C-23	1-12 2a-13 2b-26 3-1	6	17	21
19	Himmelsbach et al. Germany, Austria. 2022[38]	66	65 (30–88)	54/12	HBV-9 HCV-14 Alcohol-25 NASH-18	A-35 B-23 C-5	A-1 B-22 C-35 D-8	1-14 2-46 3-6	29	18	19
20	Iwamoto et al. Japan. 2021[39]	51	71 (37–85)	45/6	HBV-7 HCV-19 others-25	A-47 B-4	B-24 C-27	1-11 2-39 3-1	–	–	

(Table 1 continues on next page)

(Continued from previous page)

No.	Name. Country. Year[ref.]	Total N	Age (years)	Males/Females (n)	Etiology (n)	Child class (n)	BCLC (n)	Albi (n)	MVI (n)	EHM (n)	AFP > 400 ng/mL (n)
21	Kim et al. Korea. 2022[40]	86	62 (56–71)	70/16	HBV-62 HCV-3 Alcohol-11 Others-10	A-82 B-4	B-18 C-68	–	43	37	
22	Komatsu et al. Japan. 2022[41]	34	73 (45–82)	25/9	HBV-10 HCV-9 Others-15	A-32 B-2	B-15 C-19	Albi 1-11 Albi 2-23	3	13	
23	Kulkarni et al. India. 2022[42]	67	61	58/9	HBV-13 HCV-11 NASH-37 Alcohol-5 Cyrptogenic-1	A-24 B-36 C-7	BCLC-B-6 C-50 D-11	ALBI 1-31 2-24 3-12	14	12	37
24	Kuwano et al. Japan. 2022[43]	24	72 (63.8–80.8)	20/4		A-18 B-6	A-1 B-11 C-12		6	5	
25	Kuzuya et al. Japan. 2021[44]	50	73 (38–85)	44/6	HBV-11 HCV-9 Others-30	A-50	B-19 C-31	1-16 2a-17 2b-17	7	24	
26a	Lee et al. Multicentre. 2020[45]	104	62 (23–82)	84/20	HBV-51 HCV-31 Nonvira-22	A-98 B-6	B-10 C-94		55	74	37
26b	Lee et al. Multicentre. 2020[45]	60	60 (22–82)	54/6	HBV-34 HCV-11 Nonviral-15	A-60	B-6 C-54		20	40	18
27	Maesaka et al. Japan. 2021[46]	66	76 (49–93)	50/16	Viral-36 Nonviral-30	A-64 B-2	A/B-31 C-35	1/2a-35 2 b or 3-31	12	27	
28	Matsumae et al. Japan. 2022[47]	85	74 (65–80)	66/19	HBV-22 HCV-29 HBV + HCV-2 Alcohol-15 Others-17	A-81 B-4	A-6 B-31 C-48		15	38	43
29	Matsumoto et al. Japan. 2022[48]	32	77 (54–91)	19/13	HBV-4 HCV-15 Alcohol-5 NAFLD-8	A-30 B-2	B-24 C-8	1-11 2a-7 2b-14	4	4	
30	Niizeki et al. Japan. 2022[49]	152	73	118/34	HBV-22 HCV-61 Nonviral-69		A-4 B-81 C-67	1-58 2a-41 2b-53	31	43	
31	Ogawa et al. Japan. 2022[50]	33	72 (48–89)	26/7	HBV-3 HCV-8 Alcohol-3 Others-19	A-33	B-8 C-25		14	18	
32	Oura K et al. Japan. 2022[51]	41									
33	Shimose et al. Japan. 2022[52]	130	72.5 (37–93)	102/28	HBV-19 HCV-60 Alcohol-30 NASH-21		B-69 C-61	1-40 2a-45 2b-45	20	46	
34	Sho et al. Japan. 2022[53]	115	72 (31–89)	95/20	HBV-35 HCV-21 Non-viral-59	A-106 B-9	B-35 C-80	1-38 2-77	23	46	40
35	Sinner et al. Germany and Austria. 2022[54]	50	65 (50–80)	41/9	HCV-11 HBV-6 Alcohol-13 NAFLD-12/others-10	A-30 B-9 C-2	B-7 C-23 D-11	1-19 2-28 3-3	17	27	32
36	Su et al. Taiwan. 2022[55]	46	61.2	38/8	Virus-41 Nonviral-5	A-40 B-6	B-14 C-32	1-20 2-23	24	15	28
37	Takada et al. Japan. 2022[56]	27	72 (44–88)				B-14 C-13				

(Table 1 continues on next page)

(Continued from previous page)

No.	Name. Country. Year(ref.)	Total N	Age (years)	Males/Females (n)	Etiology (n)	Child class (n)	BCLC (n)	Albi (n)	MVI (n)	EHM (n)	AFP > 400 ng/mL (n)
38	Tamaki et al. Japan. 2022[57]	91	74 (68–79)	65/26	HBV-12 HCV-36 Alcohol-16 NAFLD-8 Others-19	A-77 B-13 C-1	A-1 B-40 C-50			41	
39	Tanaka et al. Japan.2022[58]	457	74 (68–79)	368/89	HCV-156 HBV-79 HCV and HBV-1 Alcohol-82 Other-139	A-427 B-30	0-7 A-21 B-172 C-257	1-162 2-292 3-3	85	154	125
40	Teng et al., Taiwan2022[59]	89	61.3 (56.4–67.8)	75/14	HBV-69 HCV-10 Non-viral-10	A-76 B-13	B-23 C-66	1-34 2-50 3-1	45	35	43
41	Tokunaga et al. Japan. 2022[60]	95				A-80 B-15	A-3 B-43 C-49	1-29 2a-26 2b-39 3-1	12	38	27
42	Tomonari et al. Japan. 2022[61]	71	71 [66–79]	58/13	HBV-8 HCV-30 Non0viral-33	A-65 B-6	A-4 B-24 C-43	1-18 2a-24 2b-27 3–2	15	24	
43	Uchikawa et al. Japan. 2022[62]	30	69 (66–73)	25/5	HBV-4 HCV-11 Nonviral-15	A-23 B-7		1–16 2a-4 2b-8 3-2	11	12	
44	Vithayathil et al. Austria, Germany, Japan, Taiwan, UK, Italy, USA. 2022[63]	191	68.4 (61.8–75.2)	161/30	NAFLD-25 Alcohol-73 HBV-37 HCV-72 Other-12	A-147 B-44	A-7 B-68 C-113	1-67 2-106 3-18	78	72	65
45	Wang et al. Taiwan. 2022[64]	48	62 (31–80)	38/10	HBV-28 HCV-13 Others-7	A-42 B-6	C-48	1-23 2-25	26	26	
46	Xin et al. China. 2022[65]	52	55.9	46/6	HBV-47 Others-5	A-52	C-52	1-43 2-9	37	26	30
47	Yamada et al. Japan. 2022[66]	20	76 (n = 8) 75 (n = 12)	17/3	HBV-8 HCV-7 Non-viral-5	A-15 B-5	B-10 C-10		3	7	8

BCLC, Barcelona Clinic Liver Cancer; ALBi, Albumin-Bilirubin; MVI, Macrovascular invasion; EHM, Extrahepatic metastasis; AFP, Alpha fetoprotein; HBV- HCV-Hepatitis C virus; Hepatitis B Virus; NASH, Non Alcoholic Steatohepatitis; NAFLD-Non-Alcoholic Fatty liver disease.

Table 1: Characteristics of the included studies.

Progression-free survival

The cumulative PFS among the 21 studies that reported PFS among 2391 patients was 6.86 months (95% CI, 6.31–7.41; $I^2 = 45.2$) (Fig. 2a). PFS was 7.1 months (95% CI, 6.52–7.64; $I^2 = 37.8$) among 2024 patients (17 studies) who received atezo-bev as first-line therapy. The mean PFS was significantly longer in patients with CTP-A cirrhosis than in those with CTP-B cirrhosis (MD: 3.83 months [95% CI, 1.81–5.84]; P < 0.001; $I^2 = 0.0$)[32,43,55,59] (Supplementary Figure S1a). Similarly, pooled PFS was longer in patients with ALBI grade 1 than ALBI grade 2 (MD: 3.07 months [95% CI, 0.44–5.7]; P = 0.02; $I^2 = 76.1$) and 3 (MD: 4.13 months [95% CI, 0.16–8.1]; P = 0.04; $I^2 = 0.0$).[23,35,43,54,55,59,62] (Supplementary Figure S1b). PFS was longer in patients receiving atezo-bev than those receiving TKIs

(MD: 2.27 months [95% CI, 0.94–3.5]; P = 0.001; $I^2 = 72.1$). When stratified by type of TKIs, PFS was significantly longer compared to sorafenib (MD: 2.6 months [95% CI, 1.06–4.13]; P = 0.001) but did not significantly differ compared to lenvatinib (MD: 1.4 months [95% CI, −0.9 to 3.7]; P = 0.23) (Supplementary Figure S1c). PFS was comparable among those who received atezo-bev as first-vs. second-line therapy (MD: 0.58 months [95% CI, −0.18 to 1.35]; P = 0.13; $I^2 = 21.7$) (Supplementary Figure S1d).

Six studies reported PFS estimates stratified by liver disease aetiology.[33,39,46,54,62,65] D'Castro et al. reported PFS of 5.1 months among patients with viral aetiology, compared to 7 and 6.2 months for those with alcohol-related liver disease and NASH, respectively. Himmelschbach et al. reported PFS of 17.3 months and 6.1

a

Study name

Progression-free survival in the cohort treated by atezo/bev

Mean and 95% CI

Study name	Mean	Lower limit	Upper limit	Total
Awiwi et al. USA. 2022	3.000	0.360	5.640	55
Charonpongsuntorn et al. Thailand. 2022 (abs.)	6.700	5.128	8.272	30
Chen et al. Taiwan. 2022	5.900	1.342	10.458	41
Cheng et al. China. 2022 (abs.)	9.700	7.541	11.859	13
Cheon et al. Korea. 2021	6.500	4.075	8.925	121
Chon et al. Korea. 2021	5.700	2.483	8.917	121
D-Alessio et al. Asia/Europe/USA. 2021	6.800	5.160	8.440	202
de Castro et al. Germany /Austria,2022	5.100	2.621	7.579	147
Finn et al. Global. 2021	6.900	5.704	8.096	336
Fulgenzi et al. (Europe, Asia and USA).2022	6.900	6.103	7.697	296
Ha et al.Korea. 2022 (abs.)	6.800	3.334	10.266	125
Himmelsbach et al. Germany,Austria.2022,	6.500	3.997	9.003	66
Kim et al,Korea,2022	5.700	3.830	7.570	78
Lee et al. Multicenter. 2020	7.300	5.422	9.178	104
Lee et al2. Multicenter. 2020	5.600	3.641	7.559	60
Matsumoto et al. Japan, 2022	6.500	5.539	7.461	32
Sho et al. Japan. 2022	6.600	5.215	7.985	115
Sinner et al. Germany and Austria. 2022	7.100	4.467	9.733	50
Xin et al. China 2022	10.600	8.386	12.814	166
Cosgrove et al. USA. 2022 (abs.)	8.700	6.417	10.983	166
Kulkarni et al. India.2022	8.000	6.071	9.929	67
Pooled	6.864	6.314	7.414	2391
Prediction Interval	6.864	5.085	8.644	

Tau2: 0.64; Q-36.47; df-20;
I^2 =45.16; P=0.01
Test of overall effect- Z=24.68;P<0.001;

0.00   3.75   7.50   11.25   15.00

b

Study name

Overall survival in the cohort treated by atezo/bev

Mean and 95% CI

Study name	Mean	Lower limit	Upper limit	Total
Awiwi et al. USA. 2022	7.900	1.155	14.645	55
Casadei-Gardini et al. 2022	16.400	8.212	24.588	864
Charonpongsuntorn et al. Thailand. 2022 (abs.)	10.200	5.274	15.126	30
Chen et al. Taiwan. 2022	13.900	7.209	20.591	41
D-Alessio et al. Asia/Europe/USA. 2021	14.900	13.558	16.242	202
D Castro et al. Germany /Austria,2022	10.800	8.172	13.428	147
Finn et al. Global. 2021	19.200	17.008	21.392	336
Fulgenzi et al. (Europe, Asia and USA).2022	15.700	14.505	16.895	296
Lee et al. Multicenter. 2020	17.100	13.839	20.361	104
Matsumoto et al. Japan, 2022	10.400	8.959	11.841	32
Sinner et al. Germany and Austria. 2022	16.100	5.957	26.243	50
Kulkarni et al. India.2022	12.000	8.333	15.667	67
Pooled	13.808	11.812	15.804	2224
Prediction Interval	13.808	7.030	20.586	

Tau²= 8.21; Q-70.93; df-11;
I^2 =84.5; P<0.001
Test of overall effect- Z=13.55;P<0.001;

0.00   7.50   15.00   22.50   30.00

Fig. 2: Forest plot of (a) cumulative progression-free survival and (b) cumulative overall survival of patients treated with atezo-bev.

months among viral and non-viral aetiology, while Lee et al. reported a PFS estimates of 4.5, 6.6, and 6.3 months for HBV, HCV and non-viral aetiologies, respectively. Sho et al. reported PFS of 6.2 months and 6.9 months among patients with viral and non-viral aetiology. While Tomonari et al. reported PFS of 9.8 and 3 months among viral and non-viral aetiology patients. Lastly, Wang et al. reported PFS of 5 months in HBV and 5.1 in HCV patients, while the PFS was 3.3 months and 5 months among non-HBV and non-HCV

patients. Cumulatively, the pooled PFS in the viral group (n = 265) was 7.44 months (95% CI, 3.83–11.1) and 5.5 (95% CI, 4.2–6.8) in the non-viral group (n = 277) (P = 0.24).

Overall survival
Among 12 studies (n = 2224 patients) that reported the OS, the pooled mean OS was 13.8 months (95% CI, 11.81–15.8; I^2 = 84.5) (Fig. 2b). The mean OS increased to 14.5 months (95% CI, 12.3–16.7; I^2 = 86.7) among

1972 patients who received atezo-bev as first-line therapy (nine studies). The mortality rate was 32.1% (95% CI, 27–37.7; 910/2684; $I^2 = 86$) among 17 reported studies (Supplementary Figure S2a). Survival in patients with CTP-A cirrhosis was longer than that in patients with CTP-B (MD: 7.19 [95% CI, 4.85–9.53]; P < 0.001; $I^2 = 0.0$) and CTP-C cirrhosis (MD: 10.1 months [95% CI, 6.32–13.85]; P < 0.001; $I^2 = 0.0$).[26,32,33,43,55,59] (Supplementary Figure S2b). Pooled mean OS was 9.1 months (95% CI, 5.97–13.82; P < 0.001; $I^2 = 27.9$) longer in ALBI grade 1 than ALBI grade 2 and 13.5 months (95% CI, 7.68–19.32; P < 0.001; $I^2 = 0$) longer in ALBI grade 1 than ALBI grade 3.[23,26,33,43] (Supplementary Figure S2c). Mortality was lower in patients treated with atezo-bev than with TKIs (OR, 0.67 [95% CI, 0.58–0.78]; P < 0.001; $I^2 = 0$)[11,24,41,47,56] (Supplementary Figure S2d). On stratifying based on the type of TKIs, mortality was significantly lower in atezo-bev group than lenvatinib (OR, 0.66 [95% CI, 0.56–0.77]; P < 0.001) but comparable with sorafenib (OR, 0.75 [95% CI, 0.51–1.1]; P = 0.14). The mean OS was similar among patients who received atezo-bev as first- or second-line therapy (MD: 3.52 months [95% CI, –1.42 to 8.46]; P = 0.16; $I^2 = 44.2$).[23,33]

Two studies reported OS, stratified by viral vs. non-viral liver disease aetiology.[33,39] D'Castro, reported higher OS in patients with non-viral (n = 97) liver disease (11.5 months vs. 8.6 months among 50 viral liver disease patients), whereas Himmelsbach et al. reported that median OS was not achieved among patients with viral aetiology (n = 23) compared to 11.8 months among those with non-viral liver disease (n = 43).

Radiological response
All studies reported performing computed tomography or magnetic resonance imaging at 6–12 weekly intervals. The cumulative ORR and DCR as per RECIST criteria were 26.7% (95% CI, 24.6–29.1; $I^2 = 42.67$) and 75.3% (95% CI, 73.1–77.4; $I^2 = 41.41$) among 33 studies (n = 3134 patients). Cumulative ORR and DCR as per mRECIST criteria were 34% (95% CI, 30.3–37.8; $I^2 = 60.3$) and 73.6% (95% CI, 68.8–78; $I^2 = 75.7$) in 25 studies (n = 1774 patients). ORR and DCR as per RECIST criteria were 29% (95% CI, 26.3–32; $I^2 = 27.7$)

and 77% (95% CI, 63.6–86.4; $I^2 = 0.0$) among 1600 patients (14 studies) who received atezo-bev as first-line therapy only. ORR and DCR as per mRECIST criteria were 40.1% (95% CI, 35.5–46.3; $I^2 = 61.1$) and 73.4% (95% CI, 64.3–81; $I^2 = 85.6$) among 971 patients (10 studies) who received atezo-bev as first-line therapy. Cumulative CR, PR, SD, and PD in 3121 patients from 32 studies assessed according to the RECIST criteria was 2.8% (95% CI, 1.9–4; $I^2 = 54.4$), 24.3% (95% CI, 22.2–26.6; $I^2 = 42.7$), 49.3% (95% CI, 46.4–52.2; $I^2 = 56.2$), and 24.8% (95% CI, 22.6–27; $I^2 = 42.7$), respectively. Cumulative CR, PR, SD, and PD rates for 1774 patients from 25 studies were 8% (95% CI, 6.1–10.2; $I^2 = 42.1$), 27.4% (95% CI, 24.4–30.6; $I^2 = 47.3$), 41% (95% CI, 36.4–45.5; $I^2 = 70.0$), and 25.2% (95% CI, 22–29; $I^2 = 60.6$), respectively, using mRECIST criteria (Table 2).

The proportion of patients who achieved ORR was lower with the RECIST than with the mRECIST criteria (OR, 0.68 [95% CI, 0.57–0.81]; P < 0.001) (Fig. 3a), whereas the proportion of patients who achieved DCR was comparable between patients evaluated by the RECIST and mRECIST criteria among the 15 studies reporting ORR/DCR including 1275 and 1263 patients (OR, 0.96 [95% CI, 0.8–1.16]; P = 0.72), respectively (Fig. 3b). The proportion of patients achieving CR and PR was lower, and SD was higher with the RECIST criteria than with the mRECIST criteria (Supplementary Figure S3a–c), although, both criteria labelled a similar proportion of patients receiving atezo-bev as having PD (Supplementary Figure S3d).

Radiological response based on the CTP score
Among four studies that reported ORR and DCR among patients with CTP-A (n = 698) and CTP-B cirrhosis (n = 83), the cumulative response rate was comparable (ORR: OR, 1.42 [95% CI, 0.77–2.6]; P = 0.25 and DCR: OR, 1.61 [95% CI, 0.92–2.82]; P = 0.09) based on RECIST criteria.[30,32,54,59] Similarly, ORR did not differ between patients with CTP-A (n = 247) and CTP-B cirrhosis (n = 57) as per mRECIST criteria (OR, 1.33 [95% CI, 0.52–3.39]; P = 0.53).[30,40,43,54] However, DCR was significantly higher in patients with CTP-A than those with CTP-B cirrhosis (OR, 2.23 [95% CI,

Response	RECIST		mRECIST	
ORR	844/3134	26.7% (24.6–29.1; $I^2 = 42.67$)	616/1774	34% (30.3–37.8; $I^2 = 60.25$)
DCR	2382/3134	75.3% (73.1–77.4; $I^2 = 41.41$)	1330/1774	73.6% (68.8–78; $I^2 = 75.66$)
CR	86/3121	2.8% (1.9–4; $I^2 = 54.38$)	135/1774	8% (6.1–10.2; $I^2 = 42.08$)
PR	755/3121	24.3% (22.2–26.6; $I^2 = 42.71$)	480/1774	27.4% (24.4–30.6; $I^2 = 47.25$)
SD	1538/3121	49.3% (46.4–52.2; $I^2 = 56.14$)	733/1774	41% (36.4–45.5; $I^2 = 70$)
PD	750/3121	24.8% (22.6–27; $I^2 = 42.73$)	426/1774	25.2% (22–29; $I^2 = 60.64$)

RECIST, Response Criteria evaluation in solid tumour; mRECIST, modified RECIST; ORR-Objective response rate; DCR, Disease Control Rate; CR, Complete Response; PR, Partial response; SD, Stable Disease; PD, Progressive Disease.

Table 2: **Cumulative radiological response among patients treated with atezolizumab-bevacizumab.**

a

Comparing RECIST and mRECIST for ORR

Study name	Odds ratio	Lower limit	Upper limit	p-Value	Recist	mRecist
Ando et al. Japan 2021	1.116	0.397	3.137	0.835	10 / 40	9 / 39
Awiwi et al. USA. 2022	1.000	0.422	2.371	1.000	15 / 48	15 / 48
Chuma et al. Japan. 2021	0.548	0.274	1.094	0.088	17 / 92	27 / 92
Finn et al. Global. 2021	0.740	0.526	1.041	0.084	89 / 304	108 / 301
Hayakawa et al. Japan 2021	0.667	0.241	1.849	0.436	8 / 46	11 / 46
Iwamoto et al.,Japan. 2021	0.624	0.266	1.464	0.279	13 / 51	18 / 51
Kim et al,Korea,2022	0.902	0.479	1.698	0.750	28 / 86	30 / 86
Kuzuya et al, Japan, 2021	0.541	0.220	1.330	0.181	11 / 47	17 / 47
Lee et al. Multicenter. 2020	0.846	0.478	1.496	0.565	37 / 99	41 / 99
Lee et al2. Multicenter. 2020	0.680	0.288	1.608	0.380	12 / 57	16 / 57
Maesaka et al. Japan.2021	0.542	0.262	1.124	0.100	19 / 64	28 / 64
Sho et al. Japan. 2022	0.549	0.286	1.056	0.073	20 / 104	29 / 96
Teng et al. Taiwan. 2022	0.759	0.367	1.570	0.458	17 / 84	21 / 84
Tomonari et al. Japan. 2022	0.700	0.304	1.613	0.403	12 / 71	16 / 71
Uchikawa et al. Japan. 2022	0.259	0.062	1.079	0.063	3 / 30	9 / 30
Xin et al. China 2022	0.385	0.173	0.854	0.019	23 / 52	35 / 52
Pooled	0.683	0.574	0.813	0.000	334 / 1275	430 / 1263

Tau2: 0.0; Q: 8.46; df-15;
I2: 0.0; P=0.94

b

Comparing RECIST and mRECIST for DCR

Study name	Odds ratio	Lower limit	Upper limit	p-Value	RECIST	mRECIST
Ando et al. Japan 2021	1.038	0.376	2.860	0.943	30 / 40	29 / 39
Awiwi et al. USA. 2022	1.000	0.446	2.240	1.000	27 / 48	27 / 48
Chuma et al. Japan. 2021	1.000	0.483	2.071	1.000	74 / 92	74 / 92
Finn et al. Global. 2021	1.055	0.715	1.555	0.787	240 / 304	235 / 301
Hayakawa et al. Japan 2021	0.822	0.343	1.968	0.660	30 / 46	32 / 46
Iwamoto et al.,Japan. 2021	1.008	0.327	3.113	0.988	44 / 51	44 / 51
Kim et al,Korea,2022	1.000	0.499	2.006	1.000	65 / 86	65 / 86
Kuzuya et al, Japan, 2021	1.000	0.341	2.934	1.000	39 / 47	39 / 47
Lee et al. Multicenter. 2020	1.000	0.527	1.898	1.000	74 / 99	74 / 99
Lee et al2. Multicenter. 2020	0.912	0.406	2.049	0.823	40 / 57	41 / 57
Maesaka et al. Japan.2021	0.782	0.353	1.731	0.544	46 / 64	49 / 64
Sho et al. Japan. 2022	0.792	0.386	1.625	0.525	83 / 104	80 / 96
Teng et al. Taiwan. 2022	1.000	0.529	1.889	1.000	55 / 84	55 / 84
Tomonari et al. Japan. 2022	0.924	0.424	2.016	0.843	54 / 71	55 / 71
Uchikawa et al. Japan. 2022	1.000	0.342	2.926	1.000	20 / 30	20 / 30
Xin et al. China 2022	1.000	0.402	2.489	1.000	40 / 52	40 / 52
Pooled	0.968	0.806	1.163	0.727	961 / 1275	959 / 1263

Tau2 =0.0; Q=1.01; df-15;
I2 =0.01; P=1
Test of overall effect- Z=-0.34;P=0.72;

Fig. 3: Forest plot comparing the (a) objective response rate and (b) disease control rate by RECIST and mRECIST criteria for patients treated with atezo-bev.

1.06–4.67]; P = 0.03) (Fig. 4a–d). A higher number of patients with CTP-B cirrhosis had PD than those with CTP-A cirrhosis, based on both RECIST and mRECIST criteria (Table 3). ORR and DCR among patients with CTP-C cirrhosis was 7.1% (95% CI, 0.004–57.7; 0/6) as reported in one study.[43]

Radiological response among patients receiving atezo-bev and TKIs

ORR was higher with atezo-bev than with TKIs according to the RECIST criteria (OR, 1.44 [95% CI, 1.01–2.04]; P = 0.04) and mRECIST criteria (OR, 1.33 [95% CI, 1.01–1.75]; P = 0.03)[11,41,47,50,56] (Supplementary Figure S4a and b). However, ORR did not significantly differ between the atezo-bev and lenvatinib-treated patients (RECIST: OR, 1.02 [95% CI, 0.64–1.61]; P = 0.91 and mRECIST: OR, 1.006 [95% CI, 0.82–4.81]; P = 0.12).

DCR was similar among atezo-bev- and TKI-treated patients using RECIST evaluation (OR, 1.18 [95% CI, 0.83–1.66]; P = 0.35)[11,41,47] (Supplementary Figure S4c). However, DCR using mRECIST evaluation was higher with atezo-bev than with TKIs (OR, 12 [95% CI,

a

Comparing the ORR among CTP A and B patients by RECIST criteria

Study name		Statistics for each study				ORR / Total		Odds ratio and 95% CI
	Odds ratio	Lower limit	Upper limit	p-Value	CTP A	CTP B	
Chuma et al. Japan. 2021	7.419	0.420	131.106	0.171	17 / 80	0 / 13	
D-Alessio et al. Asia/Europe/USA. 2021	1.322	0.533	3.276	0.547	36 / 140	7 / 34	
Sho et al. Japan. 2022	4.547	0.252	82.100	0.305	20 / 96	0 / 8	
Tanaka et al. Japan. 2022	1.167	0.482	2.824	0.733	107 / 382	7 / 28	
Pooled	1.421	0.776	2.601	0.255	180 / 698	14 / 83	
Prediction Interval							

$Tau^2 = 0.0$; Q=2.1 df-3;
$I^2 = 0.0$; P=0.55
Test of overall effect- Z=-1.13; P=0.25

b

Comparing DCR among CTP A and B by RECIST criteria

Study name		Statistics for each study				DCR / Total		Odds ratio and 95% CI
	Odds ratio	Lower limit	Upper limit	p-Value	CTP A	CTP B	
Chuma et al. Japan. 2021	4.048	1.179	13.898	0.026	66 / 80	7 / 13	
D-Alessio et al. Asia/Europe/USA. 2021	1.339	0.594	3.021	0.481	104 / 140	23 / 34	
Sho et al. Japan. 2022	0.544	0.063	4.681	0.579	76 / 96	7 / 8	
Tanaka et al. Japan. 2022	1.489	0.633	3.503	0.362	301 / 382	20 / 28	
Pooled	1.614	0.923	2.822	0.093	547 / 698	57 / 83	
Prediction Interval	1.614	0.369	7.057				

$Tau^2 = 0.03$; Q=3.35 df-3;
$I^2 = 10.48$; P=0.34
Test of overall effect- Z=-1.68; P=0.09

Fig. 4: Forest plot comparing the (a) objective response rate and (b) disease control rate by RECIST criteria (c) objective response rate, and (d) disease control rate by mRECIST criteria among CTP A and B patients treated with atezo-bev.

7.54–19.11]; P < 0.001)[11,41,47,50,56] (Supplementary Figure S4d).

A higher proportion of patients achieved CR, and a lower proportion had PD with atezo-bev therapy than with TKIs (sorafenib but not lenvatinib) using the mRECIST criteria (CR: OR, 2.08 [95% CI, 1.2–3.6]; P = 0.008; PD: 0.69 [95% CI, 0.49–0.99]; P = 0.04) but not using the RECIST criteria (CR: OR, 3.55 [95% CI, 0.97–12.91]; P = 0.05; PD: 0.84 [95% CI, 0.59–1.2]; P = 0.35). The proportion of patients who achieved PR and SD was similar between atezo-bev- and TKI-treated patients using both the RECIST and mRECIST criteria (Supplementary Figures S5a-d, S6a-d).

Radiological response among those who received atezo-bev as first-line vs. second-line therapy
In nine studies that reported, ORR (OR, 1.82 [95% CI 1.3–2.53]; P < 0.001) and DCR (OR, 1.38 [95% CI 1.008–1.89]; P = 0.04) were higher when atezo-bev was used as first-line therapy than as second-line therapy according to the RECIST criteria (Fig. 5a and b). Using the mRECIST criteria, ORR was higher when used as

first-line therapy (OR, 2.02 [95% CI 1.34–3.05]; P = 0.001) (Supplementary Figure S7a). However, the DCR did not differ based on the line of therapy (OR, 1.5 [95% CI, 0.89–2.5]; P = 0.12) (Supplementary Figure S7b). A higher proportion of patients who received atezo-bev as first-line therapy achieved a CR and PR, whereas those who received it as second-line therapy had PD according to both the RECIST and the mRECIST criteria (Supplementary Table S3).

Radiological response based on liver disease aetiology
Among four studies that report ORR using RECIST criteria stratified by liver disease aetiology, the response was comparable (OR, 1.01 [95% CI, 0.67–1.52]; P = 0.93).[34,35,41,54] (Supplementary Figure S8) Two studies reported similar DCR using RECIST criteria among viral (n = 54/70) and non-viral (n = 55/73) aetiology (OR, 1.1 [95% CI, 0.5–2.4]; P = 0.8) and another reported similar CR, PR, SD and PD by aetiology.[34,54] One study reported comparable ORR (23.5% vs. 321%; P = 0.38) and DCR (72.6% vs. 81.1%: P = 0.35) using mRECIST criteria among viral and non-viral aetiology.[54]

c

Comparing ORR among CTP A and B by mRECIST criteria

Study name	Statistics for each study				ORR / Total		Odds ratio and 95% CI
	Odds ratio	Lower limit	Upper limit	p-Value	CTP A	CTP B	
Chuma et al. Japan. 2021	15.433	0.885	269.146	0.061	29 / 80	0 / 13	
Iwamoto et al. 2021	0.517	0.067	4.022	0.529	16 / 47	2 / 4	
Sho et al. Japan. 2022	1.172	0.223	6.173	0.851	27 / 96	2 / 8	
Kulkarni et al. India. 2022	1.236	0.425	3.600	0.697	11 / 24	13 / 32	
Pooled	1.338	0.528	3.391	0.539	83 / 247	17 / 57	
Prediction Interval	1.338	0.087	20.517				

$Tau^2 = 0.17$; Q=3.67 df-3;
$I^2 = 18.38$; P=0.3
Test of overall effect- Z=0.61; P=0.53

d

Comparing DCR among CTP A and B by mRECIST criteria

Study name	Statistics for each study				DCR / Total		Odds ratio and 95% CI
	Odds ratio	Lower limit	Upper limit	p-Value	CTP A	CTP B	
Chuma et al. Japan. 2021	4.410	1.274	15.258	0.019	67 / 80	7 / 13	
Iwamoto et al. 2021	2.271	0.202	25.526	0.506	41 / 47	3 / 4	
Sho et al. Japan. 2022	1.122	0.211	5.959	0.892	74 / 96	6 / 8	
Kulkarni et al. India. 2022	1.645	0.476	5.683	0.431	19 / 24	22 / 32	
Pooled	2.232	1.065	4.674	0.033	201 / 247	38 / 57	

$Tau^2 = 0.0$; Q=2.04; df-3;
$I^2 = 0.0$; P=0.56
Test of overall effect- Z=2.12; P=0.003

Fig. 4: Continued.

Adverse events

The cumulative incidence of AEs (any grade) was 82.7% (95% CI, 77.8–86.7; 2619/3332; $I^2 = 89.3$) among 23 reported studies (Supplementary Figure S9a). The cumulative incidence of grade ≥ 3 AEs among 29 studies (n = 3855 patients) was 31.8% (95% CI, 25.6–38.7; $I^2 = 93.6$) (Supplementary Figure S9b). The proportion of patients who discontinued atezo-bev due to adverse events in 25 studies (n = 2651 patients) was 13.8% (10–18.7; $I^2 = 88.7$) (Supplementary Figure S10). Common AEs included hypertension, proteinuria, and fatigue (Table 4).

	RECIST		P	mRECIST		P
	CTP A	CTP B		CTP A	CTP B	
ORR	25.9% (22.7–29.4; 180/698)	16.8% (12–31.6; 14/83),	0.07	33.6% (28–40.1; 83/247)	30% (15.4–54.5; 17/57)	0.58
DCR	78.4% (75–81.1; 547/698)	68% (57–77.3; 57/83)	0.04	81% (75.6–85.5; 201/247)	67% (53.5–78; 38/57)	0.01
CR	3.2% (17/522)	0% (0/62)	0.14	9.8% (7/71)	13.9% (5/36)	0.53
PR	24.1% (126/522)	22.6% (14/62)	0.78	28.2% (20/71)	27.8% (10/36)	0.96
SD	51.7% (311/602)	46.7% (35/75)	0.41	48.4% (73/151)	34.7% (17/49)	0.09
PD	21.4% (129/602)	33.4% (25/75)	0.02	15.2% (23/151)	34.7% (17/49)	0.003

RECIST, Response Criteria evaluation in solid tumour; mRECIST, modified RECIST; ORR-Objective response rate; DCR, Disease Control Rate; CR, Complete Response; PR, Partial response; SD, Stable Disease; PD, Progressive Disease.

Table 3: Cumulative radiological response among patients treated with atezolizumab-bevacizumab among CTP A and B.

a   ORR among 1st line and 2nd line therapy by RECIST criteria

Study name	Odds ratio	Lower limit	Upper limit	p-Value	ORR/Total 1st line	ORR/Total 2nd line
Ando et al. Japan 2021	0.730	0.060	8.863	0.805	1 / 16	2 / 24
Awiwi et al. USA. 2022	1.535	0.445	5.296	0.498	7 / 19	8 / 29
Chuma et al. Japan. 2021	3.516	1.050	11.780	0.042	13 / 49	4 / 43
Eso et al;Japan,2021	4.000	0.953	16.791	0.058	7 / 14	5 / 25
Hayakawa et al. Japan 2021	4.149	0.738	23.333	0.106	6 / 22	2 / 24
Sho et al. Japan. 2022	0.950	0.357	2.529	0.918	9 / 48	11 / 56
Tanaka et al. Japan. 2022	1.732	1.078	2.783	0.023	74 / 229	33 / 153
Teng et al. Taiwan. 2022	2.481	0.787	7.824	0.121	12 / 45	5 / 39
Wang et al. Taiwan. 2022	1.346	0.367	4.942	0.654	8 / 27	5 / 21
Pooled	1.822	1.309	2.536	0.000	137 / 469	75 / 414

Tau^2=0.0; Q=5.98; df-8; I^2=0.0; P=0.64
Test of overall effect- Z=3.55; P<0.001

b   DCR among 1st line and 2nd line therapy by RECIST criteria

Study name	Odds ratio	Lower limit	Upper limit	p-Value	DCR/Total 1st line	DCR/Total 2nd line
Ando et al. Japan 2021	3.495	0.634	19.275	0.151	14 / 16	16 / 24
Awiwi et al. USA. 2022	1.121	0.348	3.605	0.848	11 / 19	16 / 29
Chuma et al. Japan. 2021	2.062	0.719	5.910	0.178	42 / 49	32 / 43
Eso et al;Japan,2021	1.404	0.340	5.798	0.639	10 / 14	16 / 25
Hayakawa et al. Japan 2021	4.495	1.169	17.277	0.029	18 / 22	12 / 24
Sho et al. Japan. 2022	1.184	0.450	3.112	0.732	39 / 48	44 / 56
Tanaka et al. Japan. 2022	1.252	0.763	2.056	0.374	184 / 229	117 / 153
Teng et al. Taiwan. 2022	1.122	0.455	2.763	0.803	30 / 45	25 / 39
Wang et al. Taiwan. 2022	0.799	0.231	2.758	0.722	18 / 27	15 / 21
Pooled	1.382	1.008	1.895	0.044	366 / 469	293 / 414

Tau^2=0.0; Q=5.96; df-8; I^2=0.0; P=0.65
Test of overall effect- Z=2.01; P=0.04

Fig. 5: Forest plot comparing the (a) objective response rate and (b) disease control rate by RECIST criteria among patients who received atezo-bev as 1st line vs. 2nd line therapy.

The cumulative incidence of variceal bleeding was 4.7% in 16 studies. However, only 10 studies reported details on screening for varices.[11,28,29,32,33,37,39,41,43,60] Approximately 79% (1130/1429) of patients underwent a screening endoscopy prior to atezo-bev therapy. Of these, only 46% (521/1130) of the patients had varices. Furthermore, 54% (250/465) of patients had received treatment for varices either in the form of ligation and/or nonselective beta-blocker (NSBB) (Teng et al. and Cheon et al. did not report any details on treatment). The incidence of variceal bleeding was similar for patients with CTP-A (8.55%; 29/342) and CTP-B cirrhosis (9%; 10/111) (OR, 0.83 [0.2–3.41]; P = 0.8; I^2 = 57.0).[32,37,43] The incidence of variceal bleeding was significantly higher in patients with main portal vein thrombosis (PVT) (11.6%; 24/208) than in those without PVT (6.2%; 21/376) (OR, 2.05 [1.1–3.82]; P = 0.02; I^2 = 0.0).[28,32,37,43] The incidence of variceal bleeding was similar between those who had received prior prophylactic therapy (ligation and/or NSBB) (8.2%; 7/85) and those without prior therapy (4.1%; 10/241) (OR, 2.12 [0.63–7.17]; P = 0.22; I^2 = 0.0).[37,39,43]

The cumulative incidence of immune-related AEs (iRAE) was 10.2%. Five studies reported types of iRAE.[32,33,39,51,66] The most common iRAE was hepatitis in 10 patients, followed by hypothyroidism in nine, rheumatological and musculoskeletal injury in five, skin toxicity and diarrhoea in four each, hypopituitarism, cholangitis, and rush in two each. The remaining iRAEs (pulmonary and neurologic toxicity, colitis, nephritis, mucositis, hyperparathyroidism, and type 1 diabetes mellitus) were reported in one patient each.

The incidence of grade ≥3 AEs among patients with CTP-A and CTP-B cirrhosis was comparable (OR, 0.89 [95% CI, 0.45–1.74]; P = 0.74; I^2 = 42.5)[30,32,59] (Fig. 6a). Patients treated with atezo-bev in the first-vs. second-line did not significantly differ regarding the cumulative incidence of AEs (76.2% vs. 41%; P = 0.46) and discontinuation rates (7.7% vs. 7.8; P = 0.98).[38,40,54] One study reported that the incidence of grade 3 AEs was

Adverse events	n/N	Incidence
Hypertension		
Cumulative	1082/4073	27% (23.3–31.2); I^2 = 84.42
Grade ≥3	244/3804	6% (4.7–7.8); I^2 = 64.87
Fatigue		
Cumulative	987/4060	25.1% (22.1–28.4); I^2 = 76.71
Grade ≥3	58/3753	2% (1.6–2.6); I^2 = 0.0
Anorexia		
Cumulative	623/3240	18.8% (15.8–22.2); I^2 = 76.36
Grade ≥3	46/2978	2% (1.4–2.4); I^2 = 0
Fever		
Cumulative	235/1434	16.3% (12.4–21); I^2 = 75.22
Grade ≥3	19/1344	1.8% (1.2–2.7); I^2 = 0
Proteinuria		
Cumulative	985/3822	25.2% (22.2–28.6); I^2 = 75.55
Grade ≥3	207/3445	6.3% (5.1–7.8); I^2 = 42.84
Diarrhea		
Cumulative	281/2791	9.3% (7.3–11.8); I^2 = 69.57
Grade ≥3	26/2759	1.3% (0.1–1.9); I^2 = 0.0
Gastrointestinal bleeding	128/2255	5.6% (4–8); I^2 = 70.87
Variceal bleeding	103/2062	4.7% (3.3–6.7); I^2 = 63.68
Hypothyroidism		
Cumulative	178/2591	7% (5.2–9.4); I^2 = 64.1
Grade ≥3	4/2284	0.5 (0.3–1); I^2 = 0.0
AST elevation		
Cumulative	407/1547	25% (18.1–33.2); I^2 = 90
Grade ≥3	83/1497	6.4% (5.1–8); I^2 = 9.25
Others (cumulative)		
Thrombocytopenia	228/1145	15.3% (8.4–26); I^2 = 93.3
Infusion reaction	47/762	3.4% (1.4–7.7); I^2 = 69.95
HFSR	37/1545	3.1% (1.5–6); I^2 = 67.21
iRAE	181/1537	10.2% (6.9–14.8); I^2 = 72.53

AST, aspartate transaminase; HFSR, Hand foot Skin Reaction; iRAE-immune related adverse events.

Table 4: **Cumulative adverse events among patients treated with atezolizumab-bevacizumab.**

similar between those treated with atezo-bev as first-line vs. second-line therapy.[38] Atezo-bev and TKIs had a similar cumulative incidence of any AEs (OR, 0.69 [95% CI, 0.14–3.5]; P = 0.53; I^2 = 86.5) and grade ≥3 AEs (OR, 0.86 [95% CI, 0.61–1.2]; P = 0.38; I^2 = 89.1)[11,24,41,47,50,56] (Fig. 6b). The incidence of grade 3 hypertension (OR, 1.01 [95% CI, 0.64–1.6]; P = 0.95; I^2 = 69.7) and gastrointestinal bleeding (OR, 1.55 [95% CI, 0.64–3.75]; P = 0.32; I^2 = 22.5) were similar between patients treated with atezo-bev and TKIs (Supplementary Figure S11a and b), whereas the incidence of anorexia, fatigue, diarrhoea, proteinuria, and hand-foot skin reaction were significantly higher among patients treated with TKIs (Supplementary Figure S12a-e).

Study quality and publication bias
Overall, there were 30 multicentre and 17 single-centre studies. Forty were retrospective, whereas six were prospective studies. The study by Finn et al. was the only

RCT and had a low risk of bias, except for blinding. Six studies scored 8–9 (high quality), 25 studies scored 6–7 (moderate quality), and 15 studies scored <6 (low quality) on NOS grading (Supplementary Table S4).

We included studies from several countries with different patient characteristics that were not uniformly distributed. Therefore, the heterogeneity was high for studies reporting OS but not for PFS. However, to overcome the heterogeneity, prediction interval has been provided in the Forest plot to ascertain the measured effect. There was no heterogeneity in the studies reporting OS, PFS, ORR, DCR, or incidence of grade 3 AEs in studies comparing CTP-A and CTP-B cirrhosis. Similarly, there was no heterogeneity in studies that compared PFS and radiological response for patients receiving first- and second-line atezo-bev treatment. However, there was significant heterogeneity in studies comparing PFS, ORR, and DCR, among patients receiving TKIs and atezo-bev but not in comparing mortality rate or individual grade 3 AEs. Sensitivity analysis excluding studies that reported different dosing of atezo-bev and concomitant combination of locoregional therapy and atezo-bev did not alter the cumulative results (data not shown). Similarly, when we included only high-quality studies, the results were unaffected. Funnel plot symmetry and Egger's test assessment revealed no publication bias in most outcomes (Supplementary Figures S13–S19).

Discussion
In this meta-analysis, including 5400 patients, we found that atezo-bev yielded an ORR of 26–34%, pooled PFS of 6.86 months, and OS of 13.8 months in patients with uHCC. Notably, patients with CTP-A cirrhosis had comparable ORR but significantly longer PFS and OS than patients with CTP-B cirrhosis. We also found significantly higher ORR but similar PFS and OS among those receiving atezo-bev in the first-line setting versus second-line setting (Table 5).

Most patients in the real world are not diagnosed in the early stage of HCC, and the safety and efficacy in advanced liver disease should be ascertained. The cumulative OS reported in our meta-analysis is much lower than the updated IMBrave analysis. These lower estimates is related to use in extended populations such as those with CTP-B cirrhosis, worse performance status, or in the second-line setting. Survival was better in patients with CTP-A than in those with CTP-B cirrhosis among those treated with atezo-bev. However, the radiological response and AE rates were similar. Therefore, atezo-bev can still be considered a therapeutic option for patients with CTP-B in real-world settings. A recent meta-analysis by Hajra et al. reported limited evidence to support the use of immunotherapy in patients with significant liver dysfunction.[68] However, the review included various immune-oncological agents, and only three studies

a
Comparison of grade ≥ 3 adverse events among CTP A and B

Study name		Statistics for each study				Events / Total		Odds ratio and 95% CI
		Odds ratio	Lower limit	Upper limit	p-Value	CTP A	CTP B	
Chuma et al. Japan. 2021		0.463	0.140	1.525	0.205	23 / 81	6 / 13	
D-Alessio et al. Asia/Europe/USA. 2021		1.903	0.854	4.244	0.116	47 / 154	9 / 48	
Tanaka et al. Japan. 2022		0.644	0.292	1.420	0.275	104 / 427	10 / 30	
Kulkarni et al. India.2022		0.886	0.191	4.110	0.877	3 / 24	5 / 36	
Pooled		0.893	0.457	1.745	0.741	177 / 686	30 / 127	
Prediction Interval		0.893	0.081	9.854				

Tau^2 =0.19; Q=5.21; df-3;
I^2 =42.48; P=0.15
Test of overall effect- Z=-0.33; P=0.74

b
Comparison of grade ≥ 3 adverse events among atezo/bev and TKIs

Study name	Subgroup within study	Statistics for each study				Events / Total		Odds ratio and 95% CI
		Odds ratio	Lower limit	Upper limit	p-Value	Atezo/bev	TKI	
Casadei-Gardini et al. 2022	Lenvatinib	0.435	0.365	0.519	0.000	421 / 864	921 / 1343	
Kim et al,Korea,2022	Lenvatinib	2.372	1.334	4.216	0.003	36 / 86	34 / 146	
Maesaka et al. Japan.2021	Lenvatinib	0.301	0.147	0.618	0.001	20 / 66	39 / 66	
Niizeki et al. 2022. Japan	Lenvatinib	0.372	0.231	0.599	0.000	42 / 152	77 / 152	
Su et al. Taiwan. 2022	Lenvatinib	0.536	0.217	1.324	0.177	29 / 46	35 / 46	
Pooled		0.573	0.304	1.081	0.086	548 / 1214	1106 / 1753	
Prediction Interval		0.573	0.055	5.925				
Finn et al. Global. 2021	Sorafenib	1.008	0.682	1.490	0.967	201 / 329	95 / 156	
Pooled		1.008	0.682	1.490	0.967	201 / 329	95 / 156	
Prediction Interval								
Pooled		0.863	0.619	1.204	0.387	749 / 1543	1201 / 1909	
Prediction Interval		0.863	0.141	5.280				

Tau^2 =0.63; Q=45.76; df-5;
I^2 =89.1; P<0.001
Test of overall effect- Z=-1.6; P=0.1

Fig. 6: Forest plot comparing the grade ≥3 adverse events among (a) CTP A and B patients treated with atezo-bev. (b) Among atezo-bev and tyrosine kinase inhibitors.

reported the use of atezo-bev in patients with advanced liver disease. Further studies, including more granular data on CTP-B (Child score 6/7 vs. 8 vs. 9) are required as this class includes a heterogeneous population.

One major obstacle to the use of TKIs is the lack of CR achievable by these oral drugs and there limited effects on OS. According to the current data, atezo-bev performs significantly better in achieving ORR without any added disadvantage of AEs. The incidence of hypertension and gastrointestinal bleeding is similar among patients treated with atezo-bev and those treated with TKIs. PFS and OS are similar among those who received atezo-bev as first-line and second-line therapy. However, ORR is significantly better in patients who receive atezo-bev as first-line therapy than as second-line therapy. The incidence of AEs was similar whether the drug was administered early (first-line) or late (second-line). Therefore, atezo-bev should be used as a first-line therapy for uHCC, although its use as a second-line therapy should not be discouraged.[55,61,69]

Outcome	Cumulative	CTP A vs. B	vs. TKIs	1st line vs. 2nd line
PFS	6.86 m (6.31–7.41)	MD: 3.83 m (1.81–5.84)**	MD: 2.27 m (0.94–3.5)**	MD: 0.58 m (−0.18 to 1.35)
OS	13.8 months (11.81–15.8)	MD: 7.19 (4.85–9.53)**	OR, 0.67 (0.58–0.78)**	MD:3.52 m (−1.42 to 8.46)
ORR				
RECIST	26.7% (24.6–29.1)	OR, 1.42 (0.77–2.6)	OR, 1.44 (1.01–2.04)*	OR, 1.82 (1.3–2.53)**
mRECIST	34% (30.3–37.8)	OR, 1.33 (0.52–3.39)	OR, 1.33 (1.01–1.75)*	OR, 2.02 (1.34–3.05)**
DCR				
RECIST	75.3% (73.1–77.4)	OR, 1.61 (0.92–2.82)	OR, 1.18 [0.83–1.66]	OR,1.38 (1.008–1.89)*
mRECIST	73.6% (68.8–78)	OR, 2.23 (1.06–4.67)*	OR, 12 (7.54–19.11)**	OR, 1.5 (0.89–2.5)
Grade 3 adverse events	31.8% (25.6–38.7)	OR,0.89 (0.45–1.74)	OR, 0.86 (0.61–1.2)	–

PFS, progression-free survival; OS, overall survival; m, months; MD, mean difference; OR, odds ratio; RECIST, Response Evaluation Criteria in Solid Tumours; mRECIST, modified RECIS; TKIs, Tyrosine Kinase inhibitors. *P < 0.05; **P < 0.001.

Table 5: **Major results of the meta-analysis.**

Bevacizumab, which is a vascular endothelial growth factor (VEGF) inhibitor, is associated with bleeding events including variceal bleeding. The feared complication of variceal bleeding was observed in approximately 3–5% of patients, which was much lower than expected and comparable with the corresponding proportion observed among patients treated with TKIs. The incidence of variceal bleeding was similar between patients with CTP-A and CTP-B cirrhosis and was independent of prophylactic treatment. However, patients with PVT had a higher risk of variceal bleeding. Therefore, patients with PVT should be carefully monitored for variceal bleeding as they are prone to more post-banding ulcer-related bleeding and may not benefit from prophylactic variceal ligation.

The EASL and ESMO guidelines recommend the mRECIST criteria for response evaluation for systemic therapy.[70,71] We found that a lower proportion of patients were labelled as achieving ORR and CR with the RECIST than mRECIST criteria, which is consistent with prior studies, whereas both could identify PD in a similar proportion of patients. This is expected given that the former includes total tumour burden, whereas the latter simply includes the enhancing, viable component. Due to ease of assessment, the mRECIST criteria is a better tool than the RECIST criteria in clinical practice. Further studies should explore the use of iRECIST criteria for patients receiving atezo-bev.[72]

Further real-world data are needed to compare atezo-bev with lenvatinib, given higher ORR and PFS compared to sorafenib.[73] This is particularly noteworthy in light of prolonged survival observed with lenvatinib seen in LEAP-002. Several biomarkers have been used to predict the response to immuno-oncological agents.[74,75] To date, only the baseline neutrophil-to-lymphocyte ratio, low C-reactive protein, and AFP in Immunotherapy (CRAFITY score: AFP <100 ng/mL or C-reactive protein <10 mg/L) score at baseline and decline in AFP levels at 3–6 weeks, and low serum VEGF at 3 weeks post-therapy, have been reported to predict the response to atezo-bev.[28–30,34,36,58,60,65] Programmed cell death-ligand 1 (PD-L1) expression on tumours has also been variably reported to predict the response.[76,77] Molecular correlates such as intratumoral high expression of CD274 and CD8$^+$ T cell density is associated with improved outcomes while high regulatory T cell to effector T cell ratio and expression of oncofetal genes was associated with poorer response to atezo-bev.[78] Future studies should aim to elucidate and validate simple biomarkers (at baseline) to predict the response to atezo-bev for better prognostication.

Initial studies suggested poorer response to immune-oncological agents in patients with NASH due to aberrant T-cell activation and impaired immune surveillance.[11,79] In the current study, the radiological response rate and PFS were similar among viral and non-viral HCC, though this is not a purely NASH population. Results were discordant between the two studies, with data for OS stratified by liver disease aetiology. Overall, current results suggest the effectiveness of atezo-bev does not significantly differ by liver disease aetiology. A recent post-hoc analysis of IMBrave150 similarly suggested no difference in efficacy by liver disease etiology.[80] These results may be related to the complementary enhancement of the immune microenvironment by bevacizumab, which may overcome impaired immune surveillance reported in patients with NASH.[79,81]

The meta-analysis had some limitations, with heterogeneity being the most important limitation. However, as we included several studies from real-world data from different countries, heterogeneity in terms of tumour characteristics, aetiology, liver cirrhosis severity, and assessment of tumour response was expected and may limit the generalisability of the findings. Secondly, 60% of the patients in our meta-analysis had viral aetiology, which may be argued as one of the reasons for the better response to atezo-bev than TKIs.[79] The keywords differed for each search engine, which may introduce bias in study selection. Although the studies comparing atezo-bev vs. TKI were based on five retrospective studies with good NOS scoring and one RCT, further large prospective studies and RCTs are required to confirm these findings. Few of the sub-group analyses were based on <4 studies, and data on AEs were derived from retrospective studies, which affects the cumulative results reported here. Lastly, the efficacy of only atezo-bev therapy without any LRT could not be assessed as several studies included a combination of LRT with atezo-bev, which is the current practice to improve the survival of patients with advanced HCC.

In conclusion, atezo-bev is a highly effective and safe therapy for patients with uHCC. Atezo-bev may be more beneficial when used as first-line therapy than as second-line therapy for patients with uHCC and in patients with CTP-A and CTP-B cirrhosis; however, there does not appear to be a significant difference in effectiveness by liver disease aetiology. Continued research is needed to identify treatment response biomarkers, beyond these clinical features, to select patients who benefit most from atezo-bev.

Articles

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.eclinm.2023.102179.

References

1 Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. *Nat Rev Dis Prim.* 2021;7(1):6.
2 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. *Hepatology.* 2021;73 Suppl 1(Suppl 1):4–13.
3 Kumar A, Acharya SK, Singh SP, et al. 2019 update of Indian National Association for Study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the puri II recommendations. *J Clin Exp Hepatol.* 2020;10(1):43–80.
4 Agarwal PD, Phillips P, Hillman L, et al. Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival. *J Clin Gastroenterol.* 2017;51(9):845–849.
5 Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. *Ann Surg Oncol.* 2014;21(4):1287–1295.
6 Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet.* 2018;391(10126):1163–1173.
7 Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008;359(4):378–390.
8 Kulkarni AV, Fatima S, Sharma M, et al. Lenvatinib for unresectable hepatocellular carcinoma: the first Indian experience. *Gastro-Hep.* 2021;3(6):407–408.
9 Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. *Biochim Biophys Acta Rev Cancer.* 2020;1874(1):188391.
10 Kuo YH, Lu SN, Chen YY, et al. Real-world lenvatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a propensity score matching analysis. *Front Oncol.* 2021;11:737767.
11 Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med.* 2020;382(20):1894–1905.
12 Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. *J Hepatol.* 2022;76(3):681–693.
13 Fulgenzi CAM, D'Alessio A, Airoldi C, et al. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. *Eur J Cancer.* 2022;174:57–67.
14 Vogel A, Rimassa L, Sun HC, et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. *Liver Cancer.* 2021;10(3):240–248.
15 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.
16 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis.* 2010;30(1):52–60.
17 Wells GA, Shea B, O'Connell D, et al. *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.* Oxford. 2000.
18 Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
19 Min L, Shasha F, Wei P, Yichao C, Yao Z, Huaxin D. Clinical efficacy of atezolizumab plus bevacizumab for the treatment of advanced hepato-cellular carcinoma. *Chin J Dig Surg.* 2021;20:29–31.
20 Xiaoyun H, Mengya Z, Qi L, Guosheng Y, Rong L, Jinzhang C. Clinical efficacy of atezolizumab plus bevacizumab for first-line treatment of unresectable hepatocellular carcinoma. *Chin J Dig Surg.* 2021;20:20–24.
21 Yi L, Junwei L, Guoliang S, et al. Clinical efficacy of atezolizumab plus bevacizumab in the first-line treatment of advanced hepatocellular carcinoma. *Chin J Dig Surg.* 2021;20:25–28.
22 Ando Y, Kawaoka T, Kosaka M, et al. Early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice. *Cancers (Basel).* 2021;13(16):3958.
23 Awiwi MO, Elsayes KM, Mohamed YI, et al. The prognostic value of baseline clinical and radiologic imaging features in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. *J Hepatocell Carcinoma.* 2022;9:913–927.
24 Casadei-Gardini A, Rimini M, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. *Eur J Cancer.* 2023;180:9–20.
25 Charonpongsuntorn C, Tanasanvimon S, Korphaisarn K, et al. MO5-3 Efficacy and patient-report outcomes of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma in Thailand. *Ann Oncol.* 2022;33:S484.
26 Chen CT, Feng YH, Yen CJ, et al. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. *Hepatol Int.* 2022;16(5):1199–1207.
27 Cheng J, Chen B, Jing Y, Lu Y. Efficacy and safety in advanced hepatocellular carcinoma using atezolizumab plus bevacizumab combined with interventional therapy: a retrospective analysis of real-world evidence. *J Clin Oncol.* 2022;40(16_suppl):e16112–e.
28 Cheon J, Yoo C, Hong JY, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. *Liver Int.* 2022;42(3):674–681.
29 Chon YE, Cheon J, Kim H, et al. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. *Cancer Med.* 2023;12(3):2731–2738.
30 Chuma M, Uojima H, Hattori N, et al. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis. *Hepatol Res.* 2022;52(3):269–280.
31 Cosgrove D, Tan A, Hernandez S, et al. Atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (Hcc): real-world experience from A us community Oncology network. In: *Hepatology; 2022.* Hoboken 07030-5774, NJ USA: Wiley 111 River ST; 2022:S1308–S1309.
32 D'Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in

patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. *Hepatology*. 2022;76(4):1000–1012.

33 de Castro T, Jochheim LS, Bathon M, et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. *Ther Adv Med Oncol*. 2022;14: 17588359221080298.

34 Eso Y, Takeda H, Taura K, Takai A, Takahashi K, Seno H. Pre-treatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma. *Curr Oncol*. 2021;28(5):4157–4166.

35 Fulgenzi CAM, Cheon J, D'Alessio A, et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study. *Eur J Cancer*. 2022;175:204–213.

36 Ha Y, Yang H, Cheon J, et al. Abstract. *Hepatol Int*. 2022;16(S1):1–503.

37 Ha Y, Kim JH, Cheon J, Jeon GS, Kim C, Chon HJ. Risk of variceal bleeding in patients with advanced hepatocellular carcinoma receiving atezolizumab/bevacizumab. *Clin Gastroenterol Hepatol*. 2022;21:2421.

38 Hayakawa Y, Tsuchiya K, Kurosaki M, et al. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. *Invest New Drugs*. 2022;40(2):392–402.

39 Himmelsbach V, Pinter M, Scheiner B, et al. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers. *Cancers (Basel)*. 2022;14(7):1722.

40 Iwamoto H, Shimose S, Noda Y, et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. *Cancers (Basel)*. 2021;13(11):2786.

41 Kim BK, Cheon J, Kim H, et al. Atezolizumab/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. *Cancers (Basel)*. 2022; 14(7):1747.

42 Komatsu S, Yano Y, Fujishima Y, et al. Current role of atezolizumab plus bevacizumab therapy in the sequential treatment of unresectable hepatocellular carcinoma. *Anticancer Res*. 2022; 42(3):1403–1412.

43 Kulkarni AV, Krishna V, Kumar K, et al. Safety and efficacy of atezolizumab-bevacizumab in real world: the first Indian experience. *J Clin Exp Hepatol*. 2023;13(4):618–623.

44 Kuwano A, Yada M, Narutomi F, et al. Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/beta-catenin signal activation. *Oncol Lett*. 2022;24(1):216.

45 Kuzuya T, Kawabe N, Hashimoto S, et al. Early changes in alpha-fetoprotein are a useful predictor of efficacy of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma. *Oncology*. 2022;100(1):12–21.

46 Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. *Lancet Oncol*. 2020;21(6):808–820.

47 Maesaka K, Sakamori R, Yamada R, et al. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. *Hepatol Res*. 2022;52(7):630–640.

48 Matsumae T, Kodama T, Myojin Y, et al. Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy. *Cancers (Basel)*. 2022;14(14):3367.

49 Matsumoto H, Tsuchiya K, Nakanishi H, et al. Clinical usefulness of monitoring muscle volume during atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma. *Cancers (Basel)*. 2022;14(14):3551.

50 Niizeki T, Tokunaga T, Takami Y, et al. Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a propensity score matching analysis. *Target Oncol*. 2022;17(6):643–653.

51 Ogawa K, Kanzaki H, Chiba T, et al. Effect of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma harboring CTNNB1 mutation in early clinical experience. *J Cancer*. 2022;13(8):2656–2661.

52 Oura K, Morishita A, Kei T, et al. Abstract. *Hepatol Int*. 2022;16(S1):1–503.

53 Shimose S, Iwamoto H, Tanaka M, et al. Association between adverse events and prognosis in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter retrospective study. *Cancers (Basel)*. 2022;14(17):4284.

54 Sho T, Suda G, Yamamoto Y, et al. Efficacy and effect on liver functional reserve of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet eligibility criteria of IMbrave150. *Cancers (Basel)*. 2022;14(16):3938.

55 Sinner F, Pinter M, Scheiner B, et al. Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience. *Cancers (Basel)*. 2022;14(23):5966.

56 Su CW, Teng W, Lin PT, et al. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. *Cancer Med*. 2023;12(6):7077–7089.

57 Takada H, Maekawa S, Enomoto N. Significance of plasma IP-10/CXCL10 levels in patients treated with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma. In: *Hepatology; 2022*. Hoboken 07030-5774, NJ USA: Wiley 111 River ST; 2022:S1364.

58 Tamaki N, Tada T, Kurosaki M, et al. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. *Invest New Drugs*. 2022;40(6):1290–1297.

59 Tanaka T, Hiraoka A, Tada T, et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. *Hepatol Res*. 2022;52(9):773–783.

60 Teng W, Lin CC, Su CW, et al. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. *Am J Cancer Res*. 2022;12(4):1899–1911.

61 Tokunaga T, Tateyama M, Kondo Y, et al. Optimal management of atezolizumab plus bevacizumab therapy for patients with unresectable hepatocellular carcinoma focusing on therapeutic modifications. In: *Hepatology; 2022*. Hoboken 07030-5774, NJ USA: Wiley 111 River ST; 2022:S1351–S1352.

62 Tomonari T, Tani J, Sato Y, et al. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. *Cancer Med*. 2023;12(3):2646–2657.

63 Uchikawa S, Kawaoka T, Fujino H, et al. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography. *J Med Ultrason*. 2023;50(1):57–62.

64 Vithayathil M, D'Alessio A, Fulgenzi CAM, et al. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. *Liver Int*. 2022;42(11):2538–2547.

65 Wang JH, Chen YY, Kee KM, et al. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. *Cancers (Basel)*. 2022;14(2).

66 Xin Y, Cao F, Yang H, et al. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. *Front Immunol*. 2022;13:929141.

67 Yamada T, Minami T, Tateishi R, Koike K. Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor. *Liver Int*. 2021;41(9):2233–2234.

68 El Hajra I, Sanduzzi-Zamparelli M, Sapena V, et al. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. *Hepatology*. 2023;77(4):1139–1149.

69 Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology*. 2023. https://doi.org/10.1097/HEP.0000000000000466.

70 Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(Suppl 4):iv238–i255.

71 European Association for the Study of the Liver, Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018;69(1):182–236.

72 Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncol.* 2017;18(3):e143–e152.

73 Finn R, Kudo M, Merle P, et al. LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). *Ann Oncol.* 2022;33:S1401.

74 Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? *Expert Rev Gastroenterol Hepatol.* 2022;16(4):333–339.

75 Singal AG, Hoshida Y, Pinato DJ, et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma. *Gastroenterology.* 2021;160(7):2572–2584.

76 Rizzo A, Ricci AD, Di Federico A, et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand? *Front Oncol.* 2021;11:803133.

77 Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. *Eur J Cancer.* 2022;177:175–185.

78 Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. *Nat Med.* 2022;28(8):1599–1611.

79 Pfister D, Nunez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature.* 2021; 592(7854):450–456.

80 Espinoza M, Muquith M, Lim M, Zhu H, Singal AG, Hsiehchen D. Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150. *Gastroenterology.* 2023;165(1):286–288 e4.

81 Hatanaka T, Kakizaki S, Hiraoka A, et al. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: a Japanese multicenter observational study. *Cancer Med.* 2023;12(5):5293–5303.